First Manhattan
AVEO

First Manhattan’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

First Manhattan’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-100
Closed – – 1493
2016
Q2 		$0 Hold
100
– – ﹤0.01% 1545
2016
Q1 		$0 Buy
+100
New +$990 ﹤0.01% 1475

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DVC
Deer VI & Co Larchmont, New York $2.23M AUM 9.32% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

First Manhattan's AVEO Position: Q3 2016 in Review

First Manhattan sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q3 2016, closing a stake of 100 shares.

First Manhattan first reported a position in AVEO in Q1 2016 and held it in 2 quarters. The position peaked at $0 in Q2 2016. 44 funds tracked by Wall St. Rank hold AVEO as of Q3 2016.

  • First Manhattan reported no remaining AVEO Pharmaceuticals, Inc. position as of Q3 2016 after selling out during the quarter.
  • First Manhattan sold 100 AVEO Pharmaceuticals, Inc. shares in Q3 2016.
  • First Manhattan first reported a position in AVEO Pharmaceuticals, Inc. in Q1 2016 and held it in 2 quarters.
  • First Manhattan's AVEO Pharmaceuticals, Inc. position peaked at $0 in Q2 2016.
  • 44 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q3 2016.

Based on First Manhattan's 13F filing for Q3 2016, filed 20 Oct 2016.